Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
复制标题
异氯酸盐脱氢酶1基因突变与临床低级神经胶质瘤的预后有关。
DOI：
10.1371/journal.pone.0130872
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Jiang T
中科院分区：
文献类型：
--
作者：
Li MY;Wang YY;Cai JQ;Zhang CB;Wang KY;Cheng W;Liu YW;Zhang W;Jiang T
异柠檬酸脱氢酶1基因突变在大多数世界卫生组织II级和III级胶质瘤和继发性胶质母细胞瘤中发现。已知异柠檬酸脱氢酶1突变在高级别胶质瘤中具有预后价值。然而，它们在低级别胶质瘤中的预后意义仍然存在争议。我们确定了异柠檬酸脱氢酶1状态在低级别胶质瘤中的预测和预后价值。还评估了异柠檬酸脱氢酶1状态与临床病理和遗传因素的相关性。从中国胶质瘤基因组图谱数据库中收集417例低级别胶质瘤的临床和遗传学资料，包括异柠檬酸脱氢酶1突变、O 6甲基鸟嘌呤DNA甲基转移酶启动子甲基化、1 p/19 q染色体丢失和TP 53突变。采用Kaplan-Meier和考克斯比例风险回归分析评价临床特征和分子生物学标志物对预后的影响。异柠檬酸脱氢酶1突变被确定为总体生存的独立预后因素，但不是无进展生存。值得注意的是，异柠檬酸脱氢酶1突变被发现是少突胶质细胞瘤患者的一个重要预后因素，但在星形细胞瘤患者中不是。此外，在异柠檬酸脱氢酶1突变型肿瘤中，O 6-甲基鸟嘌呤DNA甲基转移酶启动子甲基化（p = 0.017）和TP 53突变（p < 0.001）的发生频率高于异柠檬酸脱氢酶1野生型肿瘤，而1 p/19 q缺失（p = 0.834）的发生频率则不高。年轻患者年龄（p = 0.041）和额叶位置（p = 0.010）与异柠檬酸脱氢酶1突变显著相关。化疗对异柠檬酸脱氢酶1突变型肿瘤患者的生存率没有改善。异柠檬酸脱氢酶1突变是低级别胶质瘤的独立预后因素，但对化疗反应无预测价值。异柠檬酸脱氢酶1突变与O 6甲基鸟嘌呤DNA甲基转移酶启动子甲基化和TP 53突变高度相关。
Isocitrate dehydrogenase 1 gene mutations are found in most World Health Organization grade II and III gliomas and secondary glioblastomas. Isocitrate dehydrogenase 1 mutations are known to have prognostic value in high-grade gliomas. However, their prognostic significance in low-grade gliomas remains controversial. We determined the predictive and prognostic value of isocitrate dehydrogenase 1 status in low-grade gliomas. The association of isocitrate dehydrogenase 1 status with clinicopathological and genetic factors was also evaluated. Clinical information and genetic data including isocitrate dehydrogenase 1 mutation, O 6-methylguanine DNA methyltransferase promoter methylation, 1p/19q chromosome loss, and TP53 mutation of 417 low-grade gliomas were collected from the Chinese Glioma Genome Atlas database. Kaplan–Meier and Cox proportional hazards regression analyses were performed to evaluate the prognostic effect of clinical characteristics and molecular biomarkers. Isocitrate dehydrogenase 1 mutation was identified as an independent prognostic factor for overall, but not progression-free, survival. Notably, isocitrate dehydrogenase 1 mutation was found to be a significant prognostic factor in patients with oligodendrogliomas, but not in patients with astrocytomas. Furthermore, O 6-methylguanine DNA methyltransferase promoter methylation (p = 0.017) and TP53 mutation (p < 0.001), but not 1p/19q loss (p = 0.834), occurred at a higher frequency in isocitrate dehydrogenase 1-mutated tumors than in isocitrate dehydrogenase 1 wild-type tumors. Younger patient age (p = 0.041) and frontal lobe location (p = 0.010) were significantly correlated with isocitrate dehydrogenase 1 mutation. Chemotherapy did not provide a survival benefit in patients with isocitrate dehydrogenase 1-mutated tumors. Isocitrate dehydrogenase 1 mutation was an independent prognostic factor in low-grade gliomas, whereas it showed no predictive value for chemotherapy response. Isocitrate dehydrogenase 1 mutation was highly associated with O 6-methylguanine DNA methyltransferase promoter methylation and TP53 mutation.
登录
查看更多内容
影响因子：
45.3
作者：
Sanson, Marc;Marie, Yannick;Delattre, Jean-Yves
通讯作者：
Delattre, Jean-Yves
DOI：
10.1097/00005072-199710000-00003
发表时间：
1997-10-01
影响因子：
3.2
作者：
Maintz, D;Fiedler, K;vonDeimling, A
通讯作者：
vonDeimling, A
DOI：
10.1126/science.1164382
发表时间：
2008-09-26
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Parsons DW;Jones S;Zhang X;Lin JC;Leary RJ;Angenendt P;Mankoo P;Carter H;Siu IM;Gallia GL;Olivi A;McLendon R;Rasheed BA;Keir S;Nikolskaya T;Nikolsky Y;Busam DA;Tekleab H;Diaz LA Jr;Hartigan J;Smith DR;Strausberg RL;Marie SK;Shinjo SM;Yan H;Riggins GJ;Bigner DD;Karchin R;Papadopoulos N;Parmigiani G;Vogelstein B;Velculescu VE;Kinzler KW
通讯作者：
Kinzler KW
影响因子：
15.9
作者：
Ichimura K;Pearson DM;Kocialkowski S;Bäcklund LM;Chan R;Jones DT;Collins VP
通讯作者：
Collins VP
影响因子：
11.5
作者：
Gorovets, Daniel;Kannan, Kasthuri;Huse, Jason T.
通讯作者：
Huse, Jason T.